Daily busulfan plus melphalan and autologous stem cell transplantation for high-risk solid tumors: pharmacokinetic studies and clinical results

Andrew M Yeager, C. Qsowski, R. Mullins, C. Kaplan, M. Bover, S. Devine, K. Forte, M. Lauer, M. Mogul, E. Oison, T. Oison, C. Turner, R. Vega

Research output: Contribution to journalArticle

Abstract

The lack of effective preparative regimens limits the treatment of highrisk solid tumors by autologous stem cell transplantation (ASCT). We evaluated ASCT after single dairy dose busulfan (BU; 160 mg/W/dose p.o. x 4 days) and melphalan (MEL; 140 mg/m2 i.v. x 1) and determined BU pharmacokinetics in 10 patients (pis) (median age, 15 yr; range, 3-47) with relapsed or refractory Ewing's sarcoma (2), neuroblastoma (1), osteosarcoma (1), ovarian dysgerminoma (1), seminoma (1), testicular carcinoma (1), primitive neuroectodermal tumor (1), Wilms' tumor (1), or hepatoblastoma (1). Pts received ASCT with bone marrow (3 pts), peripheral blood progenitor cells (4 pts), or both (3 pts). Median peak BU concentrations were 6.96 umol/L (range, 3.77-11.31) in the 4 pédiatrie pts and 12.63 umol/L (range, 6.55-18.23) in the 6 adult pts (P=NS; Wilcoxon rank-sum test). Median BU area under the curve (AUC) was 1S36 umol/L.min (range, 1623-3SS8) in pédiatrie pts and 4856 umol/L.min (range, 2571-7470) in adult pts (P<0.01, Wilcoxon rank-sum test). Median BU half-life was 129 min (range, 114-148) in pédiatrie pts and 174 min (range, 102-214) in adults (P=NS). All pts developed mucositis but none developed hepatic veno-occlusive disease. Median time to ANOO.S x lO'/L was 11 days (range, 10-17) and to platelets >20 x lO'/L was 17 days (range, 11-21) post-ASCT. Two pts (1 neuroblastoma, 1 osteosarcoma) relapsed at 3 and 5 months, respectively, after ASCT and died with progressive tumor. Eight pts remain in remission at a median of 8 months (range, 1.5-17.5+) after ASCT. Our findings demonstrate significantly different BU AUCs between pédiatrie and adult pts given daily body surface area-based BU dosing. Daily BU plus MEL and ASCT is a well-tolerated regimen that may provide durable relapsefree survival in pts with refractory solid tumors.

Original languageEnglish (US)
Pages (from-to)816
Number of pages1
JournalExperimental Hematology
Volume25
Issue number8
StatePublished - 1997
Externally publishedYes

Fingerprint

Busulfan
Melphalan
Stem Cell Transplantation
Pharmacokinetics
Neoplasms
Osteosarcoma
Nonparametric Statistics
Neuroblastoma
Area Under Curve
Dysgerminoma
Hepatoblastoma
Primitive Neuroectodermal Tumors
Seminoma
Ewing's Sarcoma
Wilms Tumor
Neoplastic Stem Cells
Body Surface Area
Clinical Studies
Blood Cells
Stem Cells

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Daily busulfan plus melphalan and autologous stem cell transplantation for high-risk solid tumors : pharmacokinetic studies and clinical results. / Yeager, Andrew M; Qsowski, C.; Mullins, R.; Kaplan, C.; Bover, M.; Devine, S.; Forte, K.; Lauer, M.; Mogul, M.; Oison, E.; Oison, T.; Turner, C.; Vega, R.

In: Experimental Hematology, Vol. 25, No. 8, 1997, p. 816.

Research output: Contribution to journalArticle

Yeager, AM, Qsowski, C, Mullins, R, Kaplan, C, Bover, M, Devine, S, Forte, K, Lauer, M, Mogul, M, Oison, E, Oison, T, Turner, C & Vega, R 1997, 'Daily busulfan plus melphalan and autologous stem cell transplantation for high-risk solid tumors: pharmacokinetic studies and clinical results', Experimental Hematology, vol. 25, no. 8, pp. 816.
Yeager, Andrew M ; Qsowski, C. ; Mullins, R. ; Kaplan, C. ; Bover, M. ; Devine, S. ; Forte, K. ; Lauer, M. ; Mogul, M. ; Oison, E. ; Oison, T. ; Turner, C. ; Vega, R. / Daily busulfan plus melphalan and autologous stem cell transplantation for high-risk solid tumors : pharmacokinetic studies and clinical results. In: Experimental Hematology. 1997 ; Vol. 25, No. 8. pp. 816.
@article{9a61a62f8cc744fbab7595d5c4f60ca6,
title = "Daily busulfan plus melphalan and autologous stem cell transplantation for high-risk solid tumors: pharmacokinetic studies and clinical results",
abstract = "The lack of effective preparative regimens limits the treatment of highrisk solid tumors by autologous stem cell transplantation (ASCT). We evaluated ASCT after single dairy dose busulfan (BU; 160 mg/W/dose p.o. x 4 days) and melphalan (MEL; 140 mg/m2 i.v. x 1) and determined BU pharmacokinetics in 10 patients (pis) (median age, 15 yr; range, 3-47) with relapsed or refractory Ewing's sarcoma (2), neuroblastoma (1), osteosarcoma (1), ovarian dysgerminoma (1), seminoma (1), testicular carcinoma (1), primitive neuroectodermal tumor (1), Wilms' tumor (1), or hepatoblastoma (1). Pts received ASCT with bone marrow (3 pts), peripheral blood progenitor cells (4 pts), or both (3 pts). Median peak BU concentrations were 6.96 umol/L (range, 3.77-11.31) in the 4 p{\'e}diatrie pts and 12.63 umol/L (range, 6.55-18.23) in the 6 adult pts (P=NS; Wilcoxon rank-sum test). Median BU area under the curve (AUC) was 1S36 umol/L.min (range, 1623-3SS8) in p{\'e}diatrie pts and 4856 umol/L.min (range, 2571-7470) in adult pts (P<0.01, Wilcoxon rank-sum test). Median BU half-life was 129 min (range, 114-148) in p{\'e}diatrie pts and 174 min (range, 102-214) in adults (P=NS). All pts developed mucositis but none developed hepatic veno-occlusive disease. Median time to ANOO.S x lO'/L was 11 days (range, 10-17) and to platelets >20 x lO'/L was 17 days (range, 11-21) post-ASCT. Two pts (1 neuroblastoma, 1 osteosarcoma) relapsed at 3 and 5 months, respectively, after ASCT and died with progressive tumor. Eight pts remain in remission at a median of 8 months (range, 1.5-17.5+) after ASCT. Our findings demonstrate significantly different BU AUCs between p{\'e}diatrie and adult pts given daily body surface area-based BU dosing. Daily BU plus MEL and ASCT is a well-tolerated regimen that may provide durable relapsefree survival in pts with refractory solid tumors.",
author = "Yeager, {Andrew M} and C. Qsowski and R. Mullins and C. Kaplan and M. Bover and S. Devine and K. Forte and M. Lauer and M. Mogul and E. Oison and T. Oison and C. Turner and R. Vega",
year = "1997",
language = "English (US)",
volume = "25",
pages = "816",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Daily busulfan plus melphalan and autologous stem cell transplantation for high-risk solid tumors

T2 - pharmacokinetic studies and clinical results

AU - Yeager, Andrew M

AU - Qsowski, C.

AU - Mullins, R.

AU - Kaplan, C.

AU - Bover, M.

AU - Devine, S.

AU - Forte, K.

AU - Lauer, M.

AU - Mogul, M.

AU - Oison, E.

AU - Oison, T.

AU - Turner, C.

AU - Vega, R.

PY - 1997

Y1 - 1997

N2 - The lack of effective preparative regimens limits the treatment of highrisk solid tumors by autologous stem cell transplantation (ASCT). We evaluated ASCT after single dairy dose busulfan (BU; 160 mg/W/dose p.o. x 4 days) and melphalan (MEL; 140 mg/m2 i.v. x 1) and determined BU pharmacokinetics in 10 patients (pis) (median age, 15 yr; range, 3-47) with relapsed or refractory Ewing's sarcoma (2), neuroblastoma (1), osteosarcoma (1), ovarian dysgerminoma (1), seminoma (1), testicular carcinoma (1), primitive neuroectodermal tumor (1), Wilms' tumor (1), or hepatoblastoma (1). Pts received ASCT with bone marrow (3 pts), peripheral blood progenitor cells (4 pts), or both (3 pts). Median peak BU concentrations were 6.96 umol/L (range, 3.77-11.31) in the 4 pédiatrie pts and 12.63 umol/L (range, 6.55-18.23) in the 6 adult pts (P=NS; Wilcoxon rank-sum test). Median BU area under the curve (AUC) was 1S36 umol/L.min (range, 1623-3SS8) in pédiatrie pts and 4856 umol/L.min (range, 2571-7470) in adult pts (P<0.01, Wilcoxon rank-sum test). Median BU half-life was 129 min (range, 114-148) in pédiatrie pts and 174 min (range, 102-214) in adults (P=NS). All pts developed mucositis but none developed hepatic veno-occlusive disease. Median time to ANOO.S x lO'/L was 11 days (range, 10-17) and to platelets >20 x lO'/L was 17 days (range, 11-21) post-ASCT. Two pts (1 neuroblastoma, 1 osteosarcoma) relapsed at 3 and 5 months, respectively, after ASCT and died with progressive tumor. Eight pts remain in remission at a median of 8 months (range, 1.5-17.5+) after ASCT. Our findings demonstrate significantly different BU AUCs between pédiatrie and adult pts given daily body surface area-based BU dosing. Daily BU plus MEL and ASCT is a well-tolerated regimen that may provide durable relapsefree survival in pts with refractory solid tumors.

AB - The lack of effective preparative regimens limits the treatment of highrisk solid tumors by autologous stem cell transplantation (ASCT). We evaluated ASCT after single dairy dose busulfan (BU; 160 mg/W/dose p.o. x 4 days) and melphalan (MEL; 140 mg/m2 i.v. x 1) and determined BU pharmacokinetics in 10 patients (pis) (median age, 15 yr; range, 3-47) with relapsed or refractory Ewing's sarcoma (2), neuroblastoma (1), osteosarcoma (1), ovarian dysgerminoma (1), seminoma (1), testicular carcinoma (1), primitive neuroectodermal tumor (1), Wilms' tumor (1), or hepatoblastoma (1). Pts received ASCT with bone marrow (3 pts), peripheral blood progenitor cells (4 pts), or both (3 pts). Median peak BU concentrations were 6.96 umol/L (range, 3.77-11.31) in the 4 pédiatrie pts and 12.63 umol/L (range, 6.55-18.23) in the 6 adult pts (P=NS; Wilcoxon rank-sum test). Median BU area under the curve (AUC) was 1S36 umol/L.min (range, 1623-3SS8) in pédiatrie pts and 4856 umol/L.min (range, 2571-7470) in adult pts (P<0.01, Wilcoxon rank-sum test). Median BU half-life was 129 min (range, 114-148) in pédiatrie pts and 174 min (range, 102-214) in adults (P=NS). All pts developed mucositis but none developed hepatic veno-occlusive disease. Median time to ANOO.S x lO'/L was 11 days (range, 10-17) and to platelets >20 x lO'/L was 17 days (range, 11-21) post-ASCT. Two pts (1 neuroblastoma, 1 osteosarcoma) relapsed at 3 and 5 months, respectively, after ASCT and died with progressive tumor. Eight pts remain in remission at a median of 8 months (range, 1.5-17.5+) after ASCT. Our findings demonstrate significantly different BU AUCs between pédiatrie and adult pts given daily body surface area-based BU dosing. Daily BU plus MEL and ASCT is a well-tolerated regimen that may provide durable relapsefree survival in pts with refractory solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=33748605089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748605089&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748605089

VL - 25

SP - 816

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 8

ER -